 -	 ٧.			-	*	+				٠				_		*	v	⊏'	v	è
 	 _		_			 _	 	_4	 a		/_1	7.	L.	У	<u>c.</u>		 دار	Ε.	ŀ	
 	 	۳.			- 48	 -		_	ш				_	_						

HM12/1210

ADVISORY ACTION

FLEHR HOHBACH TEST ALBRITTON & HERBERT SUITE 3400 FOUR EMBARCADERO STREET SAN FRANCISCO CA 94111

EXAN	AINER
- 20115	
SAOUD ART UNIT	PAPER NUMBER
1646	19

DATE MAILED: 12/10/99

Below is a communication from the EXAMINER in charge of this application COMMISSIONER OF PATENTS AND TRADEMARKS

		•	
PECHONSE			
PERIOD FOR RESPONSE:		from the date of the final rejection	
			In no
expires three months from the covert however, will the statutor	date of the final rejection or as of the y period for the response expire late	e mailing date of this Advisory Action, whichever is later. er than six months from the date of the final rejection.	iate fee.
Any extension of time must be The date on which the respons purposes of determining the per	obtained by filing a petition under 3 in se, the petition, and the fee have be period of extension and the correspon and ate of the originally set shortened	For filed is the date of the response and also the date for the filed is the date of the response and also the date for inding amount of the fee. Any extension fee pursuant to 3 is statutory period for response or as set forth in b) above.	
Appellant's Brief is due in accorda	nce with 37 CFR 1.192(a).	as been considered with the following effect, but it is not on the entered and the final rejection stands because:	deemed
Applicant's response to the final re to place the application in conditio	n for allowance:	not be entered and the final rejection stands because:	
The proposed amendments to	the claim and /or specification will n	iot be entered and the manner and was not ea	rlier
a. There is no convincing	showing under 37 CFR 1.116(b) why	y the proposed amendment is necessary and was not ear	
presented.	that would require further considerat	tion and/or search. (See Note).	
c. They raise the issue of	to place the application in better for	rm for appeal by materially reducing or simplifying the issu	ues for
appeal.		secoding number of finally rejected claims.	
e They present addition	al claims without cancelling a corres	sponding number of finally rejected claims.	
			t cancelling
	ed claims would	d be allowed if submitted in a separately filed amendment	Cauceming
. Newly proposed or amend the non-allowable claims.	90 Claims	e entered \square will not be entered and the status of the cl	aims will
Upon the filing an appeal, to be as follows:	he proposed amendment Will be	5 (III.O.)	
Claims allowed:	NONE		
Claims objected to:	NONE NONE 1-14		
Claims rejected:			
However; Applicant's response	has overcome the following rejection	n(s):	
The afficient outsite or re	equest for reconsideration has been	considered but does not overcome the rejection because	
4. The affidavit, exhibit of to	affached		
5. The affidavit or exhibit wil	Il not be considered because applica	ant has not shown good and sufficent reasons why it was	not earlier
presented.	tion 🗌 has 🗌 has not been ap	pproved by the examiner.	
	-		
Other			
			- 12 m 2 %

PTOL-303 (REV. 5-89)

Advisory action - Paper No. 19

5

10

15

20

25

Applicant urges that Pötgens cannot anticipate the present claims because it teaches that none of the mutants examined inhibited native VEGF. A careful reading of the reference reveals that what Pötgens in fact teaches is that its mutants did not inhibit wild-type VEGF in a mitotic assay.

Applicant's argument would be persuasive if the claims required inhibition of mitotic activity. What the claims do require, however, is that the claimed mutant "be capable of inhibiting a biological activity of a native VEGF protein." This limitation would be met by a mutant which inhibits any biological activity of any native VEGF. Such activity could be, for example, the ability of native VEGF to compete for binding to the same receptor in a given biological system. See the specification at 10, paragraph bridging to 11. Indeed, Fig. 6 of the Pötgens reference demonstrates that the several mutants do in fact compete with native VEGF for binding to its receptor. The evidence of record suggests that because the prior art mutants differ in structure and qualitative biological properties from at least one native VEGF, they are more likely than not to inherently possess functional attributes which meet the broadest reasonable construction of the claims.

Examiner Saoud is on leave until February of 2000. In the interim, any inquiry concerning this communication should be directed to David Fitzgerald at telephone number (703) 308-3934 or fax number (703) 308-0294. Inquiries of a general nature should be directed to the Technology Center 1600 receptionists at (703) 308-0196.

DAVID L. FITZGERALD

PRIMARY EXAMINER
ART UNIT 1646

9 December 1999